Peer-reviewed articles were identified from MEDLINE, International Pharmaceutical Abstracts, and Current Contents (all from 1966 to August 2010) using the search terms heart failure with preserved ...

(UPDATED) Full results of the EMPEROR-Preserved trial affirm that empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) lowers the risk of CV death/hospitalization for heart failure in patients ...

Ejection fraction refers to how much blood the heart pumps out during a contraction. An abnormal ejection fraction can be a sign of heart failure. Some people might need treatment to improve their ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

Treatment with irbesartan had no effect on all-cause mortality or distribution of mode-specific mortality rates in patients with HF who also had preserved ejection fraction, results from an analysis ...

A key opinion leader provides insight into key HFpEF treatment strategies. This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, ...

Dapagliflozin significantly reduced the risk of cardiovascular (CV) death or worsening of heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFpEF), according to ...

Credit: Getty Images. The designation is based on findings from the phase 3 EMPEROR-Preserved trial. The Food and Drug Administration (FDA) granted Breakthrough Therapy designation to empagliflozin ...

Ejection fraction (EF) measures the amount of blood pumped out of your heart's lower chambers, or ventricles. It's the percentage of blood that leaves your ventricle when your heart contracts. The ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...